Online inquiry

IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9534MR)

This product GTTS-WQ9534MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FOLH1 gene. The antibody can be applied in Prostate Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001014986.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2346
UniProt ID Q04609
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9534MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12737MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ255MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ14341MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ8771MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-306
GTTS-WQ4115MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI-505
GTTS-WQ14546MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ10229MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ2802MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW